Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US District Court for Massachusetts has granted a request by Momenta Pharmaceuticals and Sandoz for a temporary restraining order (TRO) to stop Watson and Amphastar from selling Amphastar's Enoxaparin Sodium Injection product.
Subscribe to our email newsletter
The injection product is a generic equivalent to Sanofi-aventis Lovenox.
Enoxaparin is a low molecular weight heparin for treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction.
The temporary restraining order expires on 21 October.
Watson expects to launch the product during the fourth quarter of 2011 if the plaintiffs’ request for a preliminary injunction is denied, the company said.